Effects of adjuvant therapy with 0.1% olopatadine hydrochloride ophthalmic solution on quality of life in patients with allergic rhinitis using systemic or nasal therapy

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 4, 2005, Pages 361-371

  Berger, William ^a,i   Abelson, Mark B ^g,h   Gomes, Paulo J ^g   Beck, Morris ^b   Kimura, Stephen ^c   Westbrook, Thomas ^d   Storms, William ^e   Galant, Stanley ^f  

^a Southern California Research   (United States)

^b Asthma Allergy Associates   (United States)

^c Harvard Medical School   (United States)

^d Allergy and Asthma Center of NW Florida ^*  (United States)

^e William Storms Allergy Clinic   (United States)

^f Clinical Trials of Orange County   (United States)

^g Ophthalmic Research Associates Inc   (United States)

^h SCHEPENS EYE RESEARCH INSTITUTE   (United States)

ⁱ Allergy & Asthma Associates of Northern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; EYE DROPS; LEUKOTRIENE RECEPTOR BLOCKING AGENT; OLOPATADINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ALLERGIC RHINITIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SYMPTOMATOLOGY; SYSTEMIC THERAPY;

EID: 25444435828     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61155-6     Document Type: Article

References (28)

1. Abelson MB, Smith L, Chapin M. Ocular allergic disease: mechanisms, disease sub-types, treatment. Ocul Surface. 2003;1:127-149.
2. Dykewicz MS, Fineman S. Executive summary of Joint Task Force Practice Parameters on Diagnosis and Management of Rhinitis. Ann Allergy Asthma Immunol. 1998;81(suppl):463-468.
3. Druce HM. Allergic and nonallergic rhinitis. In: Middleton EJ, Reed CE, Ellis EF, et al, eds. Allergy Principles and Practice. 5th ed. St Louis, MO: Mosby-Year Book Inc; 1998:1005-1016.
4. Nathan RA, Meltzer EO, Seiner JC, Storms W. Prevalence of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:S808-S814.
5. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 1998;81:478-518.
6. Rossoff LJ, Stempel DA, Alam R, et al. Roundtable discussion: the health and economic impact of rhinitis. Am J Manag Care. 1997;3:S8-S18.
7. Malone DC, Battista C, Arrighi HM, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol. 1997;99:22-27.
8. Centers for Disease Control and Prevention, National Center for Health Statistics. Fast stats A to Z: allergies/hay fever. Available at: http://www.cdc.gov/nchs/fastats/allergies.htm. Accessed July 22, 2005.
9. Centers for Disease Control and Prevention. Advanced Data 195. Hyattsville, MD: National Center for Health Statistics; 1996.
10. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol. 2004;11:17-33.
11. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
12. Juniper EF, Thompson AK, Roberts JN. Can the standard gamble and rating scale be used to measure quality of life in rhinoconjunctivitis? comparison with the RQLQ and SF-36. Allergy. 2003;57:201-206.
13. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol. 1999;104(pt 1):364-369.
14. Tripathi A, Patterson R. Impact of allergic rhinitis treatment on quality of life. Pharmacoeconomics. 2001;19:891-899.
15. Mroz M, Shapiro A, Abelson MB. Development of the Allergic Conjunctivitis Quality of Life Questionnaire (ACQLQ). Poster presented at: DIA 9th Annual Symposium for Quality of Life Evaluations; March 25, 2002; Hilton Head Island, SC.
16. Law AW, Reed SD, Sundy JS, Schulman KA. Direct costs of allergic rhinitis in the United States: estimates from the 1996 Medical Expenditure Panel Survey. J Allergy Clin Immunol. 2003;111:296-300.
17. Abelson MB, Welch DL. An evaluation of onset of duration of action of Patanol compared to Claritin in acute allergy conjunctivitis in the conjunctival allergen challenge model. Acta Ophthalmol Scand. 2000;78(suppl 203):60-63.
18. Lanier RQ, Abelson MB, Berger WE, et al. Comparison of the efficacy of combined fluticasone propionate and olopatadine versus combined fluticasone propionate and fexofenadine for the treatment of allergic rhinoconjunctivitis induced by conjunctival allergen challenge. Clin Ther. 2002;24:1161-1174.
19. Spangler DL, Abelson MB, Ober A, et al. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther. 2003;25:2245-2267.
20. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther. 2003;25:931-947.
21. Meltzer EO, Casale TB, Nathan RA, Thomson AK. Once daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 1999;83:311-317.
22. Juniper EF, Willms DG, Guyatt GH, et al. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis. CMAJ. 1992;147:887-892.
23. Ratner PH, van Baval JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine alone and in combination for the treatment of seasonal allergic rhinitis. J Fam Pract. 1998;47:118-125.
24. Ciprandi G, Canonica WG, Grosclaude M, Ostinelli J, Brazzola GG, Bosquet J. Effects of budesonide and fluticasone propionate in a placebo-controlled study on symptoms and quality of life in seasonal allergic rhinitis. Allergy. 2002;57:586-591.
25. Van Cauwenberge P, Juniper EF. Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis. Clin Exp Allergy. 2000;30:891-899.
26. Kaszuba SM, Baroody FM, deTineo M. Superiority of an intranasal corticosteroid compared with an oral antihistamine in the as-needed treatment of seasonal allergic rhinitis. Arch Intern Med. 2001;161:2581-2587.
27. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-87.
28. Juniper EF, Guyatt GH, Griffith LE, Ferrie PJ. Interpretation of rhinoconjunctivitis quality of life questionnaire data. J Allergy Clin Immunol. 1996;98:843-845.